Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roledumab in RhD-negative Pregnant Women
NCT02287896Phase 2Completed
- Sponsor
- LFB Group
- Start
- Apr 2014
- Primary completion
- Sep 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of roledumab in Hemolytic disease of the fetus and newborn due to RhD incompatibility (HDFN) (2 arms), sponsored by LFB Group. Primary endpoints: Apparent Clearance, Central Volume of Distribution and 4 more. Started Apr 2014; status: completed.
02
Drugs
roledumab
03
Conditions
Hemolytic disease of the fetus and newborn due to RhD incompatibility (HDFN)
Beyond the preview
Go deeper on NCT02287896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02287896.